Prokom Investments said it will sell its 33.3% stake in insulin manufacturer Bioton to generic-drug maker Polpharma for about $198 million, with additional milestone payments. Polpharma owner Jerzy Starak said the deal, set to be completed within a month, is a strategic move to biotech products, which he called the future of the pharmaceutical industry.

Related Summaries